Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. stockholders approved three proposals at the September 30, 2026 special meeting. The reverse stock split proposal authorizes the Board, in its sole discretion, to effect a split at any time on or before December 31, 2026, at a ratio from 1-for-15 to 1-for-35 (or any number in between), without reducing authorized common shares. Stockholders also approved an increase in authorized common shares from 490,000,000 to 675,000,000, to be effected in the Board’s sole discretion.
The proposals received 21,088,353 votes for the reverse split, 20,722,644 votes for the share increase, and 20,938,915 votes for adjournment. At the meeting, 21,747,865 shares were represented, approximately 65.36% of the 33,274,561 common shares issued and outstanding as of August 10, 2026.
Jasper Therapeutics, Inc. refiled its unaudited pro forma information for its acquisition of Kira Pharmaceuticals, completed July 16, 2026. Jasper issued Kira shareholders 5,195,009 voting common shares and 4,644,977 non-voting convertible preferred shares; each preferred share converts into 61 common shares, subject to certain conditions. Jasper accounted for the merger as an asset acquisition and recognized no goodwill.
The preferred-stock financing closed July 20, 2026, with 4,655,951 shares sold for approximately $132.0 million. Each common-stock holder of record immediately before the merger closing was entitled to one contingent value right per share; holders may receive a pro-rata portion of $30.0 million if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. Jasper acquired the rights and receivables under Kira's Mirador license, under which Mirador agreed to pay $12.0 million upfront and $8.0 million upon delivery of drug substance and compound, plus potential development milestones up to $108.5 million, commercial milestones up to $350.0 million and tiered royalties. Unaudited pro forma combined net loss was $7.352 million for the six months ended June 30, 2026 and $206.837 million for the year ended December 31, 2025; these illustrative figures exclude anticipated synergies, operating efficiencies and cost savings.
Jasper Therapeutics, Inc. amended its report on the completed July 16, 2026 acquisition of Kira Pharmaceuticals, adding Kira’s audited 2025 and 2024 statements, unaudited results for the six months ended June 30, 2026 and 2025, and pro forma combined financial information. Kira recorded a $3.418 million net loss and $3.451 million operating cash outflow in the first half of 2026, compared with a $1.161 million net loss and $648,000 operating cash outflow a year earlier. Its accumulated deficit was $184.2 million as of June 30, 2026; Kira’s auditors cited substantial doubt about its ability to continue as a going concern.
Jasper completed a concurrent private placement of approximately 4.7 million non-voting convertible preferred shares for $132.0 million in gross proceeds. Jasper agreed to seek a stockholder vote on conversion within 120 days after closing; if approval is not obtained within 12 months, holders may require repurchase at then-current fair market value. Under Kira’s July 13, 2026 Mirador license, Kira is entitled to $12.0 million upfront and $8.0 million upon delivery, may receive up to $458.5 million in development, regulatory and commercial milestones, and may receive tiered royalties on future net sales.
Jasper Therapeutics, Inc. (JSPR) said Herb Cross submitted his resignation on September 23, 2026, effective October 9, 2026, from his roles as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary, citing other professional endeavors. The board appointed Jeet Mahal, the company’s President and Chief Executive Officer, as interim Principal Financial Officer; Rick Ruiz, Vice President, Finance, as interim Principal Accounting Officer; and Matthew Ros, Chief Operating Officer, as interim Corporate Secretary. Each appointment takes effect when Cross’s resignation becomes effective. Ruiz joined Jasper in 2024 and has over 25 years of finance and accounting experience; he received no equity awards in connection with his promotion.
Jasper Therapeutics, Inc. is the issuer of redeemable warrants named in Nasdaq Stock Market LLC’s notification of removal from listing and/or registration. Nasdaq stated that it complied with its rules to strike the warrant class from listing and/or withdraw its registration. The warrants are exercisable in groups of ten for one share of Voting Common Stock at an exercise price of $115.00.
Jasper Therapeutics, Inc. (JSPR) is calling a virtual special stockholder meeting on September 30, 2026 to vote on three capital-structure proposals. The first would authorize the board, any time through December 31, 2026, to implement a reverse stock split of common stock at a ratio between 1‑for‑15 and 1‑for‑35, without changing the 490,000,000 authorized common shares. This is primarily intended to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after a notice received on June 3, 2026; the stock last closed at $0.6864 on September 3, 2026. The second proposal would increase authorized common shares from 490,000,000 to 675,000,000, mainly to ensure enough shares to convert 9,555,390 preferred shares issued in connection with the Kira Pharmaceuticals acquisition and a concurrent financing. As of August 10, 2026, common shares outstanding were 33,274,561. The third proposal would allow adjournment of the meeting to solicit more proxies if needed. The board recommends voting FOR all three proposals and notes that each is considered a “routine” matter for broker voting.
Jasper Therapeutics, Inc. (JSPR) reports that on August 21, 2026 it received a Nasdaq notice that, based on stockholders’ equity reported in its June 30, 2026 Form 10-Q, it no longer meets the $2,500,000 minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market under Rule 5550(b)(1).
The notice has no immediate effect on trading while Jasper remains in compliance with other continued listing standards. The company has 45 days, until October 5, 2026, to submit a compliance plan and may receive up to 180 days from August 21, 2026 to regain compliance if Nasdaq accepts the plan. Jasper currently anticipates seeking stockholder approval to convert outstanding Non-Voting Convertible Preferred Stock at a special stockholder meeting as part of regaining compliance, but states there is no assurance that approvals will be obtained, that Nasdaq will accept its plan, or that it will ultimately maintain its Nasdaq listing.
Jasper Therapeutics, Inc. (symbol JSPR) is asking stockholders at a virtual special meeting on September 30, 2026 to approve three proposals. The first would amend its certificate of incorporation to allow the board, any time on or before December 31, 2026, to implement a reverse stock split of its common stock at a ratio between 1-for-15 and 1-for-35, without changing the number of authorized common shares.
The board cites a Nasdaq notice received on June 3, 2026 that JSPR’s share price had stayed below the $1.00 minimum bid requirement; the stock closed at $0.716 on August 21, 2026. The company believes a reverse split could help regain compliance, though it may choose not to implement it even if approved.
The second proposal would increase authorized common shares from 490,000,000 to 675,000,000. This is tied to Jasper’s July 16, 2026 acquisition of Kira Pharmaceuticals and a related financing, under which Jasper issued 5,195,009 common shares and 9,555,390 preferred shares, each convertible into 61 common shares, and agreed to sell approximately 4.7 million preferred shares for about $132 million. The extra authorized shares are intended to support full conversion of this preferred stock. The third proposal would permit adjournment of the meeting to solicit more proxies if needed.
Jasper Therapeutics, Inc. has a significant shareholder group led by Velan Capital Investment Management LP and related entities reporting beneficial ownership of its voting common stock. As of August 17, 2026, Velan Capital and affiliated funds collectively may be deemed to beneficially own 3,363,347 shares, equal to approximately 9.9% of the outstanding shares, including shares underlying certain warrants and options subject to a 9.99% beneficial ownership blocker. The group previously reported on Schedule 13D, but as of this date indicates it no longer holds the securities with a purpose or effect of changing or influencing control of Jasper Therapeutics and is instead reporting on a passive ownership basis consistent with Schedule 13G.
Jasper Therapeutics reported much lower losses for the quarter ended June 30, 2026 and detailed major strategic steps. For the quarter, operating expenses were about $9.2 million, including research and development of roughly $5.1 million and general and administrative costs of about $4.1 million. Net loss was approximately $2.8 million, compared with $26.7 million in the same quarter of 2025, helped by $6.4 million of total other income, including changes in warrant liability.
As of June 30, 2026, Jasper had $7.3 million in cash and cash equivalents and total assets of about $11.8 million, with stockholders’ equity of $1.4 million. After quarter-end, Jasper closed the acquisition of Kira Pharmaceuticals and completed a concurrent $132 million PIPE financing. Management states that, supported by this financing, it believes it has sufficient capital to fund planned operations through the second half of 2028 while advancing its clinical pipeline, including KP-104, briquilimab, and KP-701.